Can a novel Kit D814V knock-in mouse model reproduce systemic mastocytosis?

A mutation placed in its own genomic locus

Earlier mouse models of mastocytosis mostly expressed the human KIT D816V sequence, and the authors note that these showed either long latency with low penetrance or features unlike human disease. This study instead used CRISPR-Cas9 to insert a conditional Kit D814V mutation — the mouse counterpart of human KIT D816V — directly into the endogenous mouse Kit locus. A floxed wild-type cassette spanning exons 17 to 21 sits ahead of the mutated exon 17, so the locus produces normal Kit protein until Cre recombination removes the wild-type block and lets the mutant be expressed from Kit's own promoter.

To restrict expression to blood-forming cells, the knock-in line was crossed to Scl-Cre-ERT2 mice. Six- to eight-week-old Scl-Cre;KitD814V fl/+ mice received 2 mg tamoxifen intraperitoneally for five consecutive days, and mutant expression in bone marrow cells was confirmed by Sanger sequencing of retro-transcribed cDNA from two mice. Wild-type littermates carrying Scl-Cre served as controls. Final tissue analysis came six weeks after induction, so the reported phenotype describes a short, early window rather than lifelong disease.

Mast cells expand in skin and internal organs

The most direct evidence for a mastocytosis-like phenotype is mast cell burden. Skin sections stained with toluidine blue showed more mast cells in induced Scl-Cre;KitD814V fl/+ mice than in Scl-Cre;KitWT littermates, quantified across 6 to 13 mice per group before tamoxifen and at final analysis. Serum murine mast cell protease-1 (mMCP-1, a chymase-family protease) rose over time, already elevated two weeks after induction, and correlated positively with skin mast cell numbers (Spearman r = 0.8788, two-tailed p = 0.002). Serum tryptase (mMCP-6) was also significantly elevated but considerably lower than mMCP-1.

Expansion was not confined to skin. Toluidine blue staining and flow cytometry of mononuclear cells detected more mast cells in stomach, spleen, liver and lung, and mast cell progenitors were expanded in hematopoietic organs. Bone marrow mast cells accumulated in clusters and expressed CD2, CD25 and, to a lesser extent, CD30 — markers the authors note are expressed in systemic mastocytosis patients. These are counts and marker profiles in mice; they support a resemblance to human disease rather than proving equivalence.

A myeloid neoplasm shortens survival to 33 days

Serial blood counts revealed a hematological neoplasm alongside the mast cell phenotype. Induced mice had elevated white and red blood cell counts relative to controls, with blood smears showing red cell polychromasia, reticulocytosis and more granulocytes, and hematocrit rose progressively. Eosinophils and basophils were above normal, while platelet values stayed within the normal range. The white cell increase was driven mainly by monocytes and granulocytes; lymphoid cells fell as a percentage, though not in absolute count, and B and T lymphocyte populations were markedly reduced in bone marrow.

Post-mortem examination found enlarged spleen and liver with loss of normal tissue architecture, severe extramedullary hematopoiesis disrupting splenic white pulp, and replacement of liver parenchyma. Myeloid cells, mostly granulocytes and CD71+ erythroid progenitors, expanded in both organs while lymphoid populations contracted. Most strikingly, mice expressing Kit D814V had a mean survival of 33 days versus wild-type littermates (13 versus 6 mice). Together these features led the authors to label the model SM-AHN, with the AHN component defined by extramedullary hematopoiesis, hepatosplenomegaly and myeloid expansion.

Bone marrow stem cells fall while mutant cells outcompete

Because Kit supports hematopoietic stem cell proliferation, the authors examined the stem and progenitor compartment. Kit D814V mice had significantly reduced c-Kit/Sca-1 double-positive cells, specifically short-term hematopoietic stem cells and multipotent progenitors, and the megakaryocytic/erythroid progenitor population was similarly affected. In methylcellulose assays, bone marrow cells produced fewer multi-lineage GEMM colonies, and although mutant cells tended to give higher initial output on replating, they generated very few colonies by the fourth replating — evidence of lost self-renewal. Total bone marrow cellularity was unchanged, and EdU labeling showed a higher proliferation rate among remaining stem cells but a lower absolute number of EdU-positive stem cells.

The picture differs outside the bone marrow: stem cells in peripheral blood and spleen were expanded and still formed colonies in methylcellulose. Competitive bone marrow transplantation made the proliferative advantage explicit — Kit D814V cells outcompeted wild-type cells and produced increased mast cells, leukocytosis, erythrocytosis and extramedullary hematopoiesis in recipients. This transplantation result is the strongest evidence that the mutation confers a cell-intrinsic advantage rather than merely correlating with disease.

Mutant mast cells depend on active KIT signaling

Bone marrow-derived mast cells from the mutant mice showed constitutively active KIT, with phosphorylation at tyrosines 703 and 719 even without stem cell factor stimulation, and downstream Stat5 and MAPK pathways active in unstimulated cells; wild-type cells responded only to stem cell factor. Mutant cells also grew faster than wild-type cells.

Three KIT-targeting tyrosine kinase inhibitors — avapritinib, elenestinib and bezuclastinib — reduced viability dose-dependently, with significantly lower IC50 values in D814V cells than in wild-type cells (three mice per group). In transplanted mice, treatment with a KIT-targeting inhibitor controlled the mutant clone and significantly reduced skin mast cells, leukocytes and reticulocytes while normalizing spleen weight. These are short-term responses in a mouse model, not evidence of durable disease control in patients.

Erythrocytosis marks the main divergence from patients

The authors are explicit that the model is not a perfect copy. Patients with SM-AHN often display anemia, whereas these mice developed erythrocytosis and elevated hematocrit. The proposed explanation is timing: the Scl-Cre-ERT2 line activates Cre early in stem and progenitor cells, including erythroid-lineage cells, so the mutant kinase is expressed in a broader compartment than the mast cell lineage alone. That interpretation is the authors' own, and it points to a design feature — promoter choice and induction timing — as the likely source of the erythroid phenotype.

The comparison with prior models sharpens what is new here. A human KIT D816V line driven by the baboon chymase promoter showed indolent systemic mastocytosis in only about 30% of animals, with 12 to 18 months of latency and variable organ involvement. A ROSA26-locus KIT D816V line expressed in stem cells produced a myeloproliferative neoplasm resembling polycythemia vera without a mastocytosis phenotype, and even a paradoxical reduction of peritoneal and skin mast cells. The authors' earlier Mx-Cre-driven Kit D814V line showed full penetrance of mast cell hyperplasia but was accompanied by B cell malignancy, a rare finding in patients. The new knock-in line is presented as more consistent and homogeneous, with a phenotype closer to SM-AHN.

A preclinical platform with a defined mismatch

For readers deciding whether to use this model, the relevant split is between the mast cell and AHN components, which track human SM-AHN reasonably well, and the erythroid component, which runs in the opposite direction. The mast cell readouts — tissue counts, mMCP-1 and mMCP-6, CD2/CD25 expression, progenitor expansion — plus the transplantable proliferative advantage and the response to three KIT inhibitors make this a practical platform for testing mutant-KIT-directed strategies. The 33-day mean survival and six-week endpoint mean it is a fast, severe model, not a model of indolent or slowly progressing disease.

The most decision-relevant caveat sits with the erythrocytosis: any study using these mice to model anemia, red cell biology or the full hematologic picture of SM-AHN should treat the erythroid arm as a model artifact tied to early Cre activation rather than as a feature of the human disease. Conversely, the strong, homogeneous mast cell and myeloid phenotype within a short window is precisely what earlier models lacked, which is the paper's central claim to usefulness.

Sources used in this answer